Evidence map›Paper›PMID 38435793›Full record

ArticleCellular and molecular bioengineering2024

Relatively Rare Populations of Invasive Cells Drive Progression of Heterogeneous Tumors.

Susan E Leggett, Molly C Brennan, Sophia Martinez, Joe Tien, Celeste M Nelson

Open access · greenAbstract read
In one paragraph

Article in Cellular and molecular bioengineering, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
2.0field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Susan E Leggett *Department of Chemical & Biological Engineering, Princeton University, 303 Hoyt Laboratory, 25 William Street, Princeton, NJ 08544 USA.ORCID https://orcid.org/0000-0001-7912-8987
Molly C Brennan *Department of Chemical & Biological Engineering, Princeton University, 303 Hoyt Laboratory, 25 William Street, Princeton, NJ 08544 USA.
Sophia MartinezDepartment of Chemical & Biological Engineering, Princeton University, 303 Hoyt Laboratory, 25 William Street, Princeton, NJ 08544 USA.
Joe TienDepartment of Biomedical Engineering, Boston University, Boston, MA 02215 USA.
Celeste M NelsonDepartment of Chemical & Biological Engineering, Princeton University, 303 Hoyt Laboratory, 25 William Street, Princeton, NJ 08544 USA.ORCID 0000-0001-9973-8870
Princeton University · USBoston University · USUniversity of Illinois Urbana-Champaign · US

Funding

New Jersey Alliance for Clinical Translational Science: NJ ACTSUL1TR003017 · NCATS · RUTGERS BIOMEDICAL/HEALTH SCIENCES-RBHS · PI PANETTIERI, REYNOLD ALEXANDER · 2019 to 2023
$28.9M
Engineered Invasive Human Breast Tumors with Integrated Capillaries and LymphaticsU01CA214292 · NCI · BOSTON UNIVERSITY (CHARLES RIVER CAMPUS) · PI NELSON, CELESTE M, TIEN, JOE Y · 2017 to 2021
$3.2M
Biophysical and Biochemical Effects of the ECM on Breast Epithelial CellsR01CA187692 · NCI · PRINCETON UNIVERSITY · PI NELSON, CELESTE M, RADISKY, DEREK C · 2015 to 2019
$2.1M
NRSA TrainingTL1TR003019 · NCATS · RUTGERS BIOMEDICAL/HEALTH SCIENCES-RBHS · PI SCOTTO, KATHLEEN W. · 2019 to 2023
$1.9M
NCATS NIH HHS TL1 TR003019NCATS NIH HHS UL1 TR003017NCI NIH HHS R01 CA187692NCI NIH HHS U01 CA214292
6 · The paper itself

Abstract

Introduction: Breast tumors often display an astonishing degree of spatial and temporal heterogeneity, which are associated with cancer progression, drug resistance, and relapse. Triple-negative breast cancer (TNBC) is a particularly aggressive and heterogeneous subtype for which targeted therapies are scarce. Consequently, patients with TNBC have a poorer overall prognosis compared to other breast cancer patients. Within heterogeneous tumors, individual clonal subpopulations may exhibit differences in their rates of growth and degrees of invasiveness. We hypothesized that such phenotypic heterogeneity at the single-cell level may accelerate tumor progression by enhancing the overall growth and invasion of the entire tumor. Methods: To test this hypothesis, we isolated and characterized clonal subpopulations with distinct morphologies and biomarker expression from the inherently heterogeneous 4T1 mouse mammary carcinoma cell line. We then leveraged a 3D microfluidic tumor model to reverse-engineer intratumoral heterogeneity and thus investigate how interactions between phenotypically distinct subpopulations affect tumor growth and invasion. Results: We found that the growth and invasion of multiclonal tumors were largely dictated by the presence of cells with epithelial and mesenchymal traits, respectively. The latter accelerated overall tumor invasion, even when these cells comprised less than 1% of the initial population. Consistently, tumor progression was delayed by selectively targeting the mesenchymal subpopulation. Discussion: This work reveals that highly invasive cells can dominate tumor phenotype and that specifically targeting these cells can slow the progression of heterogeneous tumors, which may help inform therapeutic approaches. Supplementary Information: The online version contains supplementary material available at 10.1007/s12195-023-00792-w.

Indexed as

Epithelial–mesenchymal transitionInterstitial fluid flowMorphodynamics

Identifiers

PMID38435793
PMCPMC10902221
OpenAlexW4390618653

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.